
Superpower peptides available for pre-order. Get first access.

Not FDA-approved
Bones & muscles
Thymosin beta-4
Also called Tβ4
Key takeaway
Thymosin beta-4 is a naturally occurring tissue-repair peptide involved in cell movement and healing, sold on the "research peptide" market for recovery. Its animal data are extensive, but human data are thin. In a Phase III trial in neurotrophic keratopathy, eye drops healed the corneal defect at 4 weeks in 6 of 10 treated patients versus 1 of 8 on placebo (p = 0.0656). It is banned in sport and is not FDA-approved.
- Written by
- Nav SekhonResearch Lead
- Published
- April 18, 2026
- Last updated
- November 12, 2026
At a glance
| FDA status | Not FDA-approved, sold in the wellness/gray market |
| What it is | Naturally occurring actin-regulating peptide involved in cell migration and tissue repair |
| Research | Human data limited to small early trials and Phase III eye-drop trials |
| Sport | Prohibited by WADA at all times |
| Evidence strength | Low research |
What is thymosin beta-4?
Thymosin beta-4 is a small, naturally occurring 43-amino acid peptide found in most cells and body fluids, released at sites of injury by platelets and immune cells. It plays a role in cell movement and tissue repair. It is sold through wellness and "research peptide" channels for recovery and healing, and it is not an approved medicine. (A marketed fragment of this peptide, TB-500, is catalogued separately.)
How does it work?
Thymosin beta-4 binds a cell-structure protein called actin and promotes:
- Cell migration
- The mobilization of stem and progenitor cells
- New blood-vessel formation
- Reduced inflammation and scarring
A 2005 review described thymosin beta-4 as an actin-sequestering protein that moonlights in tissue repair1, and a 2010 review traced its separate effects to several short active sites2 within the peptide. This mechanism is well characterized in laboratory and animal models of wound, eye, heart, and nervous-system repair. This describes the proposed mechanism, separate from demonstrated benefit in people.
Is it FDA-approved?
No. Thymosin beta-4 is not approved by the FDA, and it is not available through Superpower. In sport, it is prohibited at all times under the growth-factor section of the WADA list. The 2026 FDA compounding advisory meetings reviewed its marketed fragment TB-500, not the full-length peptide.
What does the research show?
The animal and laboratory base is large, but human data are limited. In rats with full-thickness skin wounds, thymosin beta-4 given on the skin or by abdominal injection increased re-epithelialization by 42%3 over saline at day 4 and by up to 61% at day 7, a measure of new skin covering the wound. In mice with blocked coronary arteries, thymosin beta-4 improved early heart-muscle cell survival and cardiac function4, and a later mouse study found it roused dormant adult epicardial cells5, from the heart's outer layer, to form blood-vessel cells. In mice with chemical eye burns, thymosin beta-4 drops sped corneal healing and reduced inflammation6, work a 2018 review traces from bench to Phase III eye-drop trials7.
According to PubMed, human experience is confined to small or early trials, such as a review of its regenerative properties8 and a randomized dose-escalation venous-ulcer study9 assessing safety and tolerability, plus eye-drop trials that reached Phase III in dry eye10. No pivotal trial has established efficacy for a general recovery or wellness use, so its marketed benefit is unproven in people. In the Phase III neurotrophic keratopathy trial11, the results were:
| Arm | Complete healing at 4 weeks |
| Treated patients | 6 of 10 |
| Placebo | 1 of 8 |
The difference (p = 0.0656) was a trend short of the usual significance cutoff.
More for bones & muscles
Sources: a review of thymosin beta-4's regenerative properties (Goldstein et al., Expert Opinion on Biological Therapy, 2012, DOI: 10.1517/14712598.2012.6347938) and a venous-ulcer study (Guarnera et al., Annals of the New York Academy of Sciences, 2007, DOI: 10.1196/annals.1415.0039), indexed on PubMed; and the WADA Prohibited List. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.